DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
Formato:	Journal article
Lenguaje:	English
Publicado:	Oxford University Press 2014

Ejemplares similares

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
por: Gupta, A, et al.
Publicado: (2013)

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
por: Gupta, A, et al.
Publicado: (2020)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
por: Robert, C, et al.
Publicado: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
por: Robert, C, et al.
Publicado: (2013)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
por: Kirkwood, J, et al.
Publicado: (2012)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
por: Flaherty, K, et al.
Publicado: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
por: K. Haslett, et al.
Publicado: (2021-05-01)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Edmund Poon, et al.
Publicado: (2017-08-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
por: Jessie Villanueva, et al.
Publicado: (2013-09-01)

Immunological effects of BRAF+MEK inhibition
por: Paolo A. Ascierto, et al.
Publicado: (2018-09-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
por: Eva Marie Erfurth, et al.
Publicado: (2024-12-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
por: Andrea Gazzin, et al.
Publicado: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
por: Tahar Sif eddine Bouchema, et al.
Publicado: (2022-11-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
por: Pacey, S, et al.
Publicado: (2016)

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
por: Anne L Estep, et al.
Publicado: (2007-12-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
por: Sara Bjursten, et al.
Publicado: (2019-11-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
por: Sarah J. Welsh, et al.
Publicado: (2015-03-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Blessie Elizabeth Nelson, et al.
Publicado: (2023-05-01)

Effect of food on capsule and granule formulations of selumetinib
por: Sarit Cohen‐Rabbie, et al.
Publicado: (2022-04-01)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
por: Hui-Ju Huang, et al.
Publicado: (2021-06-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
por: Leijen, S, et al.
Publicado: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
por: Leijen, S, et al.
Publicado: (2011)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Bengt Tholander, et al.
Publicado: (2020-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Ken Saijo, et al.
Publicado: (2022-08-01)

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
por: Anaïs Roeser, et al.
Publicado: (2019-11-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
por: Lovisa Falkman, et al.
Publicado: (2024-04-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Clare Judith Stones, et al.
Publicado: (2013-05-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Jan Leipe, et al.
Publicado: (2019-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
por: Matthew R. Kroll, et al.
Publicado: (2024-07-01)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
por: Shivshankari Rajkumar, et al.
Publicado: (2022-04-01)

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
por: J. Steininger, et al.
Publicado: (2024-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
por: I. V. Samoylenko, et al.
Publicado: (2017-11-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
por: B. Ziółkowska, et al.
Publicado: (2024-01-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
por: Michael J. Vido, et al.
Publicado: (2018-11-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
por: Zeynep Eroglu, et al.
Publicado: (2016-01-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Raphael Reinhard, MD, et al.
Publicado: (2018-03-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
por: Manrose Singh, et al.
Publicado: (2024-08-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
por: Sivakamavalli Jeyachandran
Publicado: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
por: Ariane Fizazi, et al.
Publicado: (2024-11-01)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
por: Marit A. C. Vermunt, et al.
Publicado: (2021-08-01)